Pupm&Dump trading strategy idea. $BLRX is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $2,82; stop-loss — $3,07; take-profit — $2,57; Do not view this idea as a recommendation for trading or...
SELL if price close under 2.72 for Target 2.04 SL closing up 3.04
Recently approved FDA drug, safer alternative to morphine,is awaiting DEA scheduling and tracking a great cup and handle set up.
Cup and Handle Pattern while company is approaching DEA scheduling for its newly FDA approved morphine replacement drug, Olivek.
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November...
Trevena Announces FDA Approval of OLINVYK™ (oliceridine) injection OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic OLINVYK product availability expected in fourth quarter of 2020 Company funded through year-end 2021, including OLINVYK commercialization OLINVYK will be...
TRVN runs into huge long-term resistance in the $3.50-3.75 zone, where many prior spikes went to die. However, this time, would expect a more robust attempt to sustain life above the level simply because of market context: this is retail momentum bull market now, and the stock is on the Robinhood radar.
Trevena Inc ($TRVN) reports on Friday, August 7th. This makes us a bit more skeptical and want to play more defensive. I do like how the chart is setting up and more skeptical money coming. Source: www.benzinga.com
All description on the chart. Please, don't forget to like and follow. Thank you.
Contextual immersion trading strategy idea. Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. The demand for shares of the company still looks higher than the supply. This and other conditions can cause a rise in the share price...
Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November...
If you understand the idea, push a thumb up! Have a question? Don't be shy to ask!
Waiting for the NDA resubmission news. Expecting the company presentation in 2020 BIO CEO & Investor Conference on Feb 11, 2020, to cause the market to move upward. In a possible future FDA approval for their IV oliceridine drug will cause a nice Trend up. Holding all Longs and Share positions.
correction with about 61.8% retracement. Instead it printed a 5-wave impulse. This should be good.